AbVacc

AbVacc is a private biotechnology company leveraging advanced protein engineering and immunology to create novel vaccines and antibody therapeutics against infectious diseases. Operating since 2008 in the BioCapital region of Maryland, the company's platform is designed to address the significant health and economic threats posed by emerging viral and bacterial targets, as highlighted by the COVID-19 pandemic. Their approach combines intelligent immunogen design with sophisticated antibody discovery to develop broad-spectrum protective solutions. The company brings together expertise in vaccinology, virology, bacteriology, and product development to advance its pipeline.

AbVacc's platform utilizes rational design to create 'Smart Immunogens' for inducing protective immune responses and 'Smart Probes' to isolate rare, protective antibodies for therapeutic development.

Total raised: $8.7M

AbVacc competes with large pharma infectious disease units and biotech platforms like Moderna. Its differentiation lies in a rational design approach for 'Smart Immunogens,' a dual focus on both vaccines and antibodies, and targeting both viral and antibiotic-resistant bacterial pathogens.